the Commissioner of the Food and Drug Administration should clearly communicate how the agency will use adverse event data from expanded access use when reviewing drugs and biologics for approval and marketing in the United States.
Burgess discusses the importance of FDA communication regarding drug approval processes.
Share
More from Michael Burgess
Last night, the House Committee on Rules met to report House Resolution 1602, providing for consideration of two pieces of legislation. First, the rule provides for consideration of H.R. 5349, the Crucial Communism Teaching Act, under a…
I thank the gentlewoman for yielding. Mr. Speaker, the reason we are here is because the average family of four is paying over $17,000 more per year thanks to the policies of the Biden-Harris administration and their allies in Congress. In…
I am prepared for the gentleman to close. Mr. McGOVERN. Mr. Speaker, I yield myself the balance of my time to close. Mr. Speaker, let us talk about priorities. My Republican colleagues have theirs all screwed up, and I am being really kind…
I am going to yield to Mr. Alford here in just a moment, but let me yield myself 2 minutes for the purpose of a response. It is difficult for me to sit here and be lectured about the cost of living by the gentleman from Massachusetts…
Other voices in this conversation
